8-K: Carisma Therapeutics Reports Q2 2024 Results, Highlights Progress on Cancer Immunotherapy Trials

Carisma Therapeutics announced its second quarter 2024 financial results and provided updates on its clinical trials, including initial data for its lead anti-HER2 product candidate expected by year-end.

Summary

• Carisma Therapeutics reported financial results for the second quarter of 2024 and provided updates on its clinical and research progress.
• The company's cash and cash equivalents were $40.4 million as of June 30, 2024, which is expected to fund operations into the third quarter of 2025.
• Initial data for CT-0525, a CAR-Monocyte therapy for HER2-overexpressing solid tumors, is expected by the end of 2024.
• The company completed clinical activities for the CT-0508 trial and announced a new analysis showing that 75% of evaluable HER2 3+ patients experienced a decrease in circulating tumor DNA (ctDNA).
• A development candidate for liver fibrosis is expected to be nominated in the first quarter of 2025.
• Carisma nominated its first in vivo CAR-M development candidate targeting Glypican-3 for hepatocellular carcinoma under the Moderna Collaboration.
• The company received a $2.0 million milestone payment from Moderna in July 2024.
• Carisma appointed new members to its Board of Directors and Scientific Advisory Board.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and research programs, as well as a strong collaboration with Moderna. However, the company is still in the early stages of development and has significant expenses and net losses, which tempers the overall sentiment.

Positives

• The company has made significant progress in its in vivo oncology and fibrosis programs.
• The nomination of a development candidate in collaboration with Moderna marks a significant step forward.
• Cash and cash equivalents of $40.4 million and $2.0 million received in July under the Moderna Collaboration are expected to fund the company into the third quarter of 2025.
• The company believes its robust development pipeline offers multiple potential value drivers in both the near and long term.
• Additional preclinical data for liver fibrosis will be highlighted in a poster presentation at the American Association for the Study of Liver Diseases The Liver Meeting 2024.
• The company has a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes.

Negatives

• The best overall response in the pembrolizumab sub-study was stable disease in only 1 out of 6 patients.
• Corticosteroid administration and / or loss of human leukocyte antigens (HLA) expression were key limitations to potential efficacy in three of the patients who experienced progressive disease in the pembrolizumab sub-study.
• Net loss was $11.2 million for the second quarter of 2024.
• Research and development expenses for the three months ended June 30, 2024, were $15.3 million.
• General and administrative expenses for the three months ended June 30, 2024, were $5.6 million.

Risks

• The company's cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty.
• Variances from management's estimates and assumptions could impact the company's liquidity prior to the third quarter of 2025.
• The company may not be able to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials.
• The company may not be able to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs.
• Clinical trial designs and regulatory pathways may change.
• The company may not be able to obtain and maintain necessary approvals from the FDA and other regulatory authorities.

Future Outlook

Carisma anticipates that its cash and cash equivalents of $40.4 million as of June 30, 2024, along with the $2.0 million received in July under the Moderna Collaboration, are sufficient to sustain its planned operations into the third quarter of 2025.

Management Comments

• We've achieved considerable clinical and research advancements this year, and I'm excited about our strong momentum and clear focus for the next 12 months.
• The CT-0508 program has provided us with invaluable insights. Looking ahead, we are dedicating our efforts to our lead asset, CT-0525, which is actively enrolling patients with initial data expected by the end of 2024.
• We have also made significant progress in our in vivo oncology and fibrosis programs. The nomination of a development candidate in collaboration with Moderna marks a significant step forward.
• We believe our robust development pipeline offers multiple potential value drivers in both the near and long term.

Industry Context

This announcement relates to the broader industry trend of developing innovative immunotherapies for cancer and other serious diseases. Carisma's focus on engineered macrophages and monocytes is a novel approach in the cell therapy field, which is a rapidly growing area of research and development.

Comparison to Industry Standards

• Carisma's approach to engineering macrophages and monocytes is unique in the cell therapy field.
• Other companies developing CAR T-cell therapies for solid tumors include Kite Pharma (Gilead), Novartis, and Juno Therapeutics (Bristol Myers Squibb).
• Kite Pharma's Yescarta and Tecartus are approved for certain types of lymphoma, while Novartis' Kymriah is approved for certain types of leukemia and lymphoma.
• These therapies target different antigens than Carisma's product candidates and utilize T cells instead of macrophages or monocytes.
• In the liver fibrosis space, companies like Intercept Pharmaceuticals and Gilead Sciences are developing drugs targeting different pathways.
• Intercept's Ocaliva is approved for primary biliary cholangitis and is in clinical trials for nonalcoholic steatohepatitis (NASH), a major cause of liver fibrosis.
• Gilead's selonsertib failed in Phase 3 trials for NASH, but the company continues to develop other therapies for liver diseases.
• Carisma's approach of using engineered macrophages to target liver fibrosis is novel compared to these other therapies.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the company's product candidates are successful in clinical trials and commercialized.
• Employees: The company's continued progress and financial stability could lead to job security and growth opportunities.
• Customers: If successful, the company's therapies could provide new treatment options for patients with cancer and other serious diseases.
• Suppliers: The company's growth and development could lead to increased business for its suppliers.
• Creditors: The company's ability to repay its debts depends on its future success and ability to raise additional capital.

Next Steps

• Report initial data from the Phase 1 clinical trial of CT-0525 by year-end 2024.
• Present preclinical data from the GPC3+ solid tumors development candidate at an upcoming medical meeting.
• Nominate a development candidate for the liver fibrosis program in the first quarter of 2025.
• Continue to explore the strategy of combining CAR-Monocyte with pembrolizumab or another checkpoint inhibitor in the CT-0525 program.

Key Dates

Keywords

immunotherapy, CAR-Monocyte, CAR-Macrophage, HER2, solid tumors, liver fibrosis, hepatocellular carcinoma, Glypican-3, clinical trial, biopharmaceutical, oncology, in vivo, ex vivo, Moderna, pembrolizumab, ctDNA